JANUX THERAPEUTICS INC Share Price Today: Live Updates & Key Insights

JANUX THERAPEUTICS INC share price today is $14.13, up -0.71%. The stock opened at $14.115 against the previous close of $14.16, with an intraday high of $14.25 and low of $13.795.

JANUX THERAPEUTICS INC Share Price Chart

JANUX THERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

JANUX THERAPEUTICS INC Share Price Performance

$14.13 -0.0071(-0.71%) JANX at 23 Mar 2026 01:45 PM Biotechnology
Lowest Today 13.795
Highest Today 14.25
Today’s Open 14.115
Prev. Close 14.16
52 Week High 35.34
52 Week Low 12.12
Day’s Range: Low 13.795 High 14.25
52-Week Range: Low 12.12 High 35.34
1 day return -
1 Week return +1.15
1 month return +5.16
3 month return -0.14
6 month return -40.31
1 year return -55.77
3 year return +25.55
5 year return -43.57
10 year return -

JANUX THERAPEUTICS INC Institutional Holdings

RA Capital Management, LLC 18.39

HHG PLC 7.73

BlackRock Inc 6.13

FMR Inc 5.77

State Street® SPDR® S&P® Biotech ETF 4.80

Vanguard Group Inc 4.78

Prosight Management, LP 3.93

Orbimed Advisors, LLC 3.21

State Street Corp 3.11

Point72 Asset Management, L.P. 2.81

Wellington Management Company LLP 2.65

Alyeska Investment Group, L.P. 2.14

T. Rowe Price Associates, Inc. 2.08

Vanguard Total Stock Mkt Idx Inv 2.02

Geode Capital Management, LLC 1.83

Citadel Advisors Llc 1.82

iShares Russell 2000 ETF 1.70

Woodline Partners LP 1.69

T. Rowe Price Investment Management,Inc. 1.60

Readystate Asset Management LP 1.58

Logos Global Management LP 1.54

Franklin Resources Inc 1.46

Balyasny Asset Management LLC 1.46

Janus Henderson Hrzn Biotec E2 USD 1.33

FIAM Small Cap Core CIT Cl B 1.21

Janus Henderson Global Life Sciences 1.18

Janus Henderson Global Life Sciences D 1.18

Fidelity Small Cap Growth 1.12

Janus Henderson Glb Life Scn I2 USD 1.07

Janus Global Life Science AUSD 1.02

Vanguard Institutional Extnd Mkt Idx Tr 0.86

Janus Henderson Triton D 0.75

Janus Henderson US SMID Cap Growth 0.75

Fidelity Small Cap Index 0.69

iShares Biotechnology ETF 0.66

Biotech Growth Ord 0.55

Fidelity Advisor Biotechnology I 0.53

Janus Henderson US Small Cap Growth 0.45

Janus Henderson Venture D 0.45

Strategic Advisers Fidelity US TtlStk 0.45

JANUX THERAPEUTICS INC Market Status

Strong Buy: 11

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

JANUX THERAPEUTICS INC Fundamentals

Market Cap 855.29 M

PB Ratio 0.8936

PE Ratio 0.0

Enterprise Value -89.44 M

Total Assets 1001.57 M

Volume 5037262

JANUX THERAPEUTICS INC Company Financials

Annual Revenue FY23:8467000 8.5M, FY22:8612000 8.6M, FY21:3637000 3.6M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:8612000 8.6M, FY21:3637000 3.6M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-62600000 -62.6M, FY22:-54154000 -54.2M, FY21:-32559000 -32.6M, FY20:-5255000 -5.3M, FY19:-4237000 -4.2M

Quarterly Revenue Q3/2025:10000000 10.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:439000 0.4M, Q2/2024:8897000 8.9M

Quarterly Profit Q3/2025:9499000 9.5M, Q2/2025:-541000 -0.5M, Q1/2025:-519000 -0.5M, Q3/2024:439000 0.4M, Q2/2024:8391000 8.4M

Quarterly Net worth Q3/2025:-24313000 -24.3M, Q2/2025:-33858000 -33.9M, Q1/2025:-23508000 -23.5M, Q3/2024:-28059000 -28.1M, Q2/2024:-5959000 -6.0M

About JANUX THERAPEUTICS INC & investment objective

Company Information Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 109

Industry Biotechnology

CEO Dr. David Alan Campbell Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

JANUX THERAPEUTICS INC FAQs

What is the share price of JANUX THERAPEUTICS INC today?

The current share price of JANUX THERAPEUTICS INC is $14.13.

Can I buy JANUX THERAPEUTICS INC shares in India?

Yes, Indian investors can buy JANUX THERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy JANUX THERAPEUTICS INC shares in India?

You can easily invest in JANUX THERAPEUTICS INC shares from India by:

Can I buy fractional shares of JANUX THERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of JANUX THERAPEUTICS INC?

JANUX THERAPEUTICS INC has a market cap of $855.29 M.

In which sector does JANUX THERAPEUTICS INC belong?

JANUX THERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in JANUX THERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of JANUX THERAPEUTICS INC?

The PE ratio of JANUX THERAPEUTICS INC is N/A and the PB ratio is 0.89.